Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 30, 2018 in Leukemia | 0 comments

In a nutshell

This study reviewed the evidence for stem cell transplantation (SCT) in patients with acute lymphoblastic leukemia (ALL). Researchers found that SCT is an effective treatment option in patients with high risk of ALL coming back. Matched donors or siblings are the preferred stem cell donors.

Some background

ALL is a cancer of the bone marrow. This may lead to abnormal immune system cells. It is often treated with chemotherapy to delete the abnormal cells. These are then replaced with normal cells from a donor. Sometimes, signs of ALL may return after treatment. It is important to research the safety and effectiveness of SCT in patients with ALL.

Methods & findings

Available studies and evidence for SCT in the treatment of ALL were reviewed.

Three studies in France demonstrated more effectiveness for SCT from matched donors compared to the patient’s own cells. Another study showed that patients who had matched donor cells achieved no signs of cancer after treatment. High-risk patients also had increased survival (46%) compared to those without a donor (31%). Two studies compared stem cell treatment with chemotherapy and found no difference between the treatment outcomes.

A large study of 1646 patients with ALL, received either SCT or chemotherapy. Patients who received a donor transplant had a greater overall survival (53%) compared to patients without a donor, who had chemotherapy only (45%). Preferred donors include genetically similar siblings or matched unrelated donors.

The bottom line

This study concluded that donor SCT was safer and more effective than other treatments in patients with high-risk ALL.

The fine print

This review is limited by a small number of studies available.

Published By :

Bone Marrow Transplantation

Date :

Nov 01, 2018

Original Title :

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leuke

click here to get personalized updates